Metavia Inc (MTVA)

$MTVA still a scam. Well on its way to less than a dollar and reverse split. Record time I believe. Run, run away from this garbage.

$MTVA zero volume today

$MTVA @otcmarkets Hosts Virtual Investor Presentation with H.H. Kim, CEO and President of MetaVia, and David Bautz, PhD, Senior Analyst at Zacks SCR https://buff.ly/jhPHhsc

$MTVA = Korean DONG-ST licensing shell in the US. Another early GLP-1 study with results far out — no efficacy data, no FDA path, Phases 2&3 years away. Meanwhile shares exploded (~2.3M → ~5.3M) and ~14.3M fully diluted with a huge warrant overhang. Where is the Vanoglipel FDA meeting update — pending, postponed, or cancelled?!

$MTVA Did you buy the top or something Mr?

$MTVA 5M market cap. Press release traded as high as 20 in September. Trading 1.52 as of yesterday's close.

$MTVA added

$MTVA 08:13 on Mar. 18 2026 Institutional Review Board At Clinical Pharmacology Of Miami Approves MetaVia Phase 1 Part 3 Clinical Trial Of DA-1726. #tradeideas

$MTVA MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control PR NEWSWIRE 7:00 AM ET 3/18/2026

$MTVA MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control

$MTVA = Dong-A's BITCH! MetaVia margin : 1% Dong-A ST cut : 99%

$MTVA MetaVia Announces Global IP Portfolio Supporting Vanoglipel BENZINGA 8:08 AM ET 3/12/2026 MetaVia Inc. (MTVA) , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a comprehensive global intellectual property portfolio supporting vanoglipel (DA-1241), its novel, orally available G-protein-coupled receptor 119 (GPR119) agonist. This currently includes 48 granted and pending patents across three patent families in the U.S., Europe, Japan, China and other countries, providing protection into 2035, unless extended further.

$MTVA MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035 PR NEWSWIRE 8:01 AM ET 3/12/2026

The B2i Digital team is pleased to announce that MetaVia Inc. (Nasdaq: $MTVA) is participating in the Life Sciences Virtual Investor Forum, co-hosted by Virtual Investor Conferences and Zacks Small Cap Research, on Thursday, March 12, 2026, at 10:30 AM EDT. The session will be moderated by David Bautz, PhD, Senior Analyst at Zacks Small Cap Research. The Life Sciences Virtual Investor Forum is a B2i Digital Featured Conference. For more details, please visit: https://b2idigital.com/otc-life-sciences-virtual-investor-forum Virtual Investor Conferences brings together public companies and a global audience of retail and institutional investors for live executive presentations, Q&A sessions, and on-demand replays. The platform is open to public companies listed on NYSE, Nasdaq, TSX, CSE, ASX, and the OTC Markets. MetaVia is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is developing DA-1726 for the treatment of obesity and vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin analogue functioning as a dual GLP-1 receptor and glucagon receptor agonist, which in a Phase 1 multiple ascending dose trial demonstrated best-in-class potential for weight loss, glucose control, and waist circumference reduction. Vanoglipel is a novel GPR119 agonist that promotes the release of key gut peptides and, in a Phase 2a clinical study, demonstrated direct hepatic action in addition to glucose-lowering effects. Presenting on behalf of MetaVia will be HH Kim, Chief Executive Officer and President. Prior to his current role, Mr. Kim served as General Counsel and Senior Vice President of Dong-A ST and Dong-A Socio Group, where he negotiated numerous licensing and investment transactions. He holds a Bachelor of Law degree from Soongshil University and a Juris Doctor from Washington University School of Law. To register for this presentation, visit: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5259493/metavia-inc-nasdaq-mtva?utm_source=b2i&utm_medium=marketing&utm_campaign=0326LifeSciencesVIC For more information about MetaVia, visit: https://ir.metaviatx.com Content about any specific company was provided and approved by that company or is available in the public domain. B2i Digital, Inc. has not independently verified the accuracy of the information contained herein. The content contained herein is informational only, and no content contained herein shall be considered an offer to solicit the sale of any security or make a recommendation to purchase a security. B2i Digital is not a broker-dealer or investment adviser.

$MTVA The Korean scam keeps hitting new lows. New ATL, $1.34

$MTVA "Life Sciences VIRTUAL Investor Forum"

$MTVA MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum

$MTVA can't buy, only close. Restrictions from brokerage. Closing ticker?

$MTVA RSI: 21.82, MACD: -0.7738 Vol: 0.25, MA20: 1.73, MA50: 4.66 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

$MTVA MetaVia’s strategy is shifting from "survival" to "clinical execution," backed by a leadership team with formidable regulatory clout. Recent activity reveals a focus on Clinical Operations and Data Management, signaling they are aggressively preparing the infrastructure for the high-dose titration data of DA-1726 expected in late 2026. The "bull case" is significantly strengthened by their board’s FDA pedigree. Dr. James Tursi, a board member with a track record of multiple FDA approvals and overseeing billion-dollar acquisitions, provides the regulatory "blueprint" necessary for a buyout or fast-track approval. Furthermore, over 55% of the stock is held by strategic partners like Dong-A ST, creating a stable institutional floor. Today’s presentation serves as a targeted "pump" to attract the volume needed to bridge the gap to $3.10. Reaching this level is mandatory to unlock $28M in warrant cash, transforming the company’s balance sheet without toxic dilution.

$MTVA 😂